表紙
市場調查報告書

麩質過敏症:開發中產品分析

Celiac Disease - Pipeline Review, H1 2020

出版商 Global Markets Direct 商品編碼 232849
出版日期 內容資訊 英文 85 Pages
訂單完成後即時交付
價格
麩質過敏症:開發中產品分析 Celiac Disease - Pipeline Review, H1 2020
出版日期: 2020年03月31日內容資訊: 英文 85 Pages
簡介

麩質過敏症又被稱之為麩質過敏性腸症,是攝取到含有麩質的食物時產生因為小腸黏膜受損而引發的消化及自體免疫性疾病,症狀有體重減輕,嘔吐,腹部發脹,腹痛,持續性腹瀉等。危險因素有紅斑性狼瘡,類風濕性關節炎,第一型糖尿病,自體免疫性肝疾病,乾燥症(修格蘭氏症候群),透納氏症等。可使用類固醇治療。同時也有嚴格遵守不攝取含麩質食品這樣的療法。

本報告提供麩質過敏症的治療藥的開發情形的相關調查,提供您開發中產品的概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢等資訊。

簡介

  • 調查範圍

麩質過敏症概要

治療藥的開發

  • 開發中產品的概要
  • 企業開發中的治療藥
  • 大學/機關研究中的治療藥
  • 企業開發中的產品
  • 大學/機關研究中的產品

麩質過敏症:治療藥的評估

  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

麩質過敏症的開發治療藥的企業

  • Amgen Inc
  • Amyra Biotech AG
  • Calypso Biotech SA
  • Circle33 LLC
  • enGene Inc
  • F. Hoffmann-La Roche Ltd
  • Glenmark Pharmaceuticals Ltd
  • ImmusanT Inc
  • Innovate Biopharmaceuticals Inc
  • Intrexon Corp
  • Sanofi
  • 武田藥品工業
  • Zedira GmbH

藥物簡介

麩質過敏症:暫停中的計劃

麩質過敏症:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC12072IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Celiac Disease - Pipeline Review, H1 2020, provides an overview of the Celiac Disease (Gastrointestinal) pipeline landscape.

Celiac disease is an autoimmune disorder caused by an immune response to wheat protein gluten. Symptoms include weight loss, vomiting, abdominal bloating, abdominal pain and persistent diarrhea. Risk factors include lupus, rheumatoid arthritis, type 1 diabetes, autoimmune liver disease, Sjogren's syndrome and Turner syndrome. Treatment includes steroids such as betamethasone and prednisolone. Further the treatment regime also involves adhering to strict gluten free diet.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Celiac Disease - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Celiac Disease (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Celiac Disease (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Celiac Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 4, 4, 1, 4 and 7 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.

Celiac Disease (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Celiac Disease (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Celiac Disease (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Celiac Disease (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Celiac Disease (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Celiac Disease (Gastrointestinal)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Celiac Disease (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Celiac Disease (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Celiac Disease - Overview
  • Celiac Disease - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Celiac Disease - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Celiac Disease - Companies Involved in Therapeutics Development
  • Ahead Therapeutics SL
  • Amgen Inc
  • Amyra Biotech AG
  • Anokion SA
  • AnTolRx Inc
  • Bioniz Therapeutics Inc
  • GlaxoSmithKline Plc
  • ImmunogenX LLC
  • ImmunoMolecular Therapeutics LLC
  • ImmusanT Inc
  • Innovate Biopharmaceuticals Inc
  • Parvus Therapeutics Inc
  • Precigen Inc
  • Takeda Pharmaceutical Co Ltd
  • Theravance Biopharma Inc
  • Topas Therapeutics GmbH
  • Vactech Oy
  • Zedira GmbH
  • Celiac Disease - Drug Profiles
  • AG-017 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AMG-714 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AMY-01 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AT-1715 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Biologic for Celiac Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • BNZ-2 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • BNZ-3 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Drug to Agonize Aryl Hydrocarbon Receptor for Celiac Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ERW-1041E - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • KAN-101 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • larazotide acetate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • latiglutenase - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Monoclonal Antibody to Antagonize IL-2R Beta for Celiac Disease, Oncology and Tropical Spastic Paraparesis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Nexvax-2 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Recombinant Peptides for Celiac Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit HLA-DQ2 for Celiac Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TAK-062 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TAK-101 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TD-5202 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Vaccine for Celiac Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ZED-1227 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ZED-754 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Celiac Disease - Dormant Projects
  • Celiac Disease - Discontinued Products
  • Celiac Disease - Product Development Milestones
  • Featured News & Press Releases
  • Feb 27, 2020: Anokion announces initiation of patient dosing in Phase 1 clinical trial of KAN-101 in celiac disease
  • Feb 19, 2020: Innovate Biopharmaceuticals announces acceptance of three abstracts for the 2020 Digestive Disease Week (DDW) conference
  • Feb 14, 2020: ImmunogenX starts enrolment in Phase Iib celiac disease study
  • Jan 21, 2020: Anokion announces FDA clearance of IND application for its lead program in celiac disease
  • Oct 22, 2019: Takeda Pharmaceutical: New treatment may reverse celiac disease
  • Aug 19, 2019: ActoBio Therapeutics receives IND green light for new antigen-specific immunotherapy study aimed at improving celiac patients tolerance of gluten
  • Aug 13, 2019: Innovate Biopharmaceuticals announces first patient dosed in the first phase 3 clinical trial for patients with celiac disease
  • Jul 15, 2019: Innovate Biopharmaceuticals announces corporate update and expected date for second quarter earnings release
  • Jun 25, 2019: ImmusanT discontinues phase 2 clinical trial for Nexvax2 in patients with celiac disease
  • Jun 24, 2019: Innovate Biopharmaceuticals expands its management team with the addition of Ed Sitar as Its Chief Financial Officer
  • Jun 10, 2019: Innovate Biopharmaceuticals announces the start of the first phase 3 clinical trial in Celiac Disease
  • May 21, 2019: ImmusanT presents early evidence supporting its lead therapeutic vaccine candidate during the Digestive Disease Week Annual Conference2019
  • Apr 09, 2019: ImmunogenX receives major grant from the National Institutes of Health (NIH) to conduct a clinical trial for Latiglutenase
  • Apr 02, 2019: Innovate Biopharmaceuticals to announce first quarter 2019 financial results and to provide operational progress updates on April 29, 2019
  • Mar 21, 2019: ImmusanT to present and participate in multiple upcoming industry and scientific conferences
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Celiac Disease, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Celiac Disease - Pipeline by Ahead Therapeutics SL, H1 2020
  • Celiac Disease - Pipeline by Amgen Inc, H1 2020
  • Celiac Disease - Pipeline by Amyra Biotech AG, H1 2020
  • Celiac Disease - Pipeline by Anokion SA, H1 2020
  • Celiac Disease - Pipeline by AnTolRx Inc, H1 2020
  • Celiac Disease - Pipeline by Bioniz Therapeutics Inc, H1 2020
  • Celiac Disease - Pipeline by GlaxoSmithKline Plc, H1 2020
  • Celiac Disease - Pipeline by ImmunogenX LLC, H1 2020
  • Celiac Disease - Pipeline by ImmunoMolecular Therapeutics LLC, H1 2020
  • Celiac Disease - Pipeline by ImmusanT Inc, H1 2020
  • Celiac Disease - Pipeline by Innovate Biopharmaceuticals Inc, H1 2020
  • Celiac Disease - Pipeline by Parvus Therapeutics Inc, H1 2020
  • Celiac Disease - Pipeline by Precigen Inc, H1 2020
  • Celiac Disease - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2020
  • Celiac Disease - Pipeline by Theravance Biopharma Inc, H1 2020
  • Celiac Disease - Pipeline by Topas Therapeutics GmbH, H1 2020
  • Celiac Disease - Pipeline by Vactech Oy, H1 2020
  • Celiac Disease - Pipeline by Zedira GmbH, H1 2020
  • Celiac Disease - Dormant Projects, H1 2020
  • Celiac Disease - Dormant Projects, H1 2020 (Contd..1), H1 2020
  • Celiac Disease - Discontinued Products, H1 2020

List of Figures

  • Number of Products under Development for Celiac Disease, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Top 10 Molecule Types, H1 2020
  • Number of Products by Stage and Top 10 Molecule Types, H1 2020